Lipoprotein(a) complexes with Beta2-Glycoprotein I in patients with coronary artery disease

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 1, 2012, Pages 81-89

  Wang, Jun Jun ^a   Gong, Jian Bin ^b   Li, Han Qing ^a   Niu, Dong mei ^a   Han, Ai Zhong ^a   Wu, Jia ^a   Zhang, Chun Ni ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

2 glycoprotein i; Atherosclerosis; Coronary artery disease; Lipoproteins; Oxidation

Indexed keywords

BETA2 GLYCOPROTEIN 1; LIPOPROTEIN A;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATION; STABLE CORONARY ARTERY DISEASE;

ACUTE CORONARY SYNDROME; AGED; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 84863078747     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.9340     Document Type: Article

References (41)

1. Scanu AM, Lawn RM, Berg K: Lipoprotein(a) and atherosclerosis. Ann Intern Med, 1991; 115: 209-218
2. Dahlen G, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of plasma concentrations of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation, 1986; 74: 758-765
3. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW: Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation, 1995; 91: 948-950
4. Zhuang YY, Li JJ, Wang JJ: Apolipoprotein(a) phenotypes in cardiocerebrovasculor diseases. Chem Phys Lipids, 1994; 107: 133-136
5. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest, 1991; 87: 767-771
6. Haberland ME, Fless GM, Scanu AM, Fogelman AM: Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocytemacrophages. J Biol Chem, 1992; 267: 4143-4151
7. Mahmoud SR, Periasamy S, Demetrios SS: Oxidized lipoprotein(a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytie cell line U937 to cultured endothelial cells. Atherosclerosis, 1996; 123: 103-113
8. Rand ML, Sangrar W, Hancock MA, Taylor DM, Marcovina SM, Packham MA, Koschinsky ML: Apolipoprotein(a) enhances platelet response to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol, 1998; 18: 1393-1399
9. Hoff HF, O'Neil J, Yashiro A: Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res, 1993; 34: 789-798
10. Naruszewicze M, Giroux LM, Davignon J: Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a). Chem Phys Lipids, 1994; 67-68: 167-174
11. Wang JJ, Niu DM, Meng Y, Han A, Li K, Zhang C: Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children. Clin Chim Acta, 2009; 407: 1-5
12. Wang JJ, Hu B, Kong LT, Cai H, Zhang CN: Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta, 2008; 390: 67-71
13. Wang JJ, Zhang CN, Meng Y, Han AZ, Gong JB, Li K: Elevated levels of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes. Clin Chim Acta, 2009; 408: 79-82
14. Wang JJ, Han AZ, Meng Y, Gong JB, Zhang CN, Li K, Liu YX: Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: Using different capture antibody. Clin Biochem, 2010; 43: 571-575
15. Morishita R, Ishii J, Kusumi Y, Yamada S, Komai N, Ohishi M, Nomura M, Hishida H, Niihashi M, Mitsumata M: Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vasucular wall. J Atheroscler Thromb, 2009; 16: 410-418
16. Kochl S, Fresser F, Lobentanz E, Baier G, Utermann G: Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. Blood, 1997; 90: 1482-1489
17. Lopez-Lira F, Rosales Leon L, Martinez VM, Ruiz-Ordaz BH: The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen. Biochim Biophys Acta, 2006; 1764: 815-823
18. Zhang C, Li K, Shi B, Wang X, Liu X, Qin W, Han A, Wang J: Detection of serum beta(2)-GPI-Lp(a) complexes in patients with systemic lupus erythematosus. Clin Chim Acta, 2010; 411: 395-399
19. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD: Reduced PAFacetylhydrolase activity associated with Lp (a) in patients with coronary artery disease. Atherosclerosis, 2004; 177: 193-201
20. Wang JJ, Zhang C, Gong J, Zhu Y, Fu L, Wang X, Li K: Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody. Clin Chim Acta, 2007; 385: 73-78
21. Wang JJ, Zhuang YY, Yao XD: Quantitation of plasminogen epitopes of serum lipoprotein(a) by sandwich enzyme linked immunosorbent assay. Clin Chim Acta, 1997; 265: 121-130
22. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
23. Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, Zwaal RF: Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biophys Acta, 1986; 884: 142-149
24. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y: Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation, 1999; 99: 2227-2230
25. Polz E, Kostner GM: The binding of beta 2-glycoprotein- I to human serum lipoproteins: distribution among density fractions. FEBS Lett, 1979; 102: 183-186
26. Schousboe I: beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood, 1985; 66: 1086-1091
27. Huang WN, Tso TK, Huang HY: Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus. Rheumatol Int 2007; 27: 453-458
28. Zampieri S, Iaccarino L, Ghirardello A, Tarricone E, Arienti S, Sarzi-Puttini P, Gambari P, Doria A: Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci 2005; 1051: 351-361
29. Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S, Bergmark C, Getz GS, Witztum JL, Scanu AM: Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential proinflammatory properties to human apolipoprotein (a). J Biol Chem, 2003; 278: 52841-52847
30. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med, 2005; 353: 46-57
31. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, Witztum JL: Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck study. J Am Coll Cardiol, 2006; 47: 2219-2228
32. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL: Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol, 2003; 41: 360-370
33. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH: Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Short-term and long-term immunologic responses to oxidized lowdensity lipoprotein. Circulation, 2004; 109: 3164-3170
34. McNeil PH, Simpson RJ, Chesterman CN, Krilis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A, 1990; 87: 4120-4124
35. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashtab MA, Hughes GRV: Atherogenic autoantigen- oxidized LDL complexes with beta2-glycoprotein. Immunobiology, 2003; 207: 17-22
36. Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, Yamamoto I, Yasuda T, Khamashta MA, Hughes GR, Koike T, Voelker DR, Matsuura E: Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res, 2003; 44: 716-726
37. Romero FI, Atsumi T, Tinahones FJ, Gómez-Zumaquero JM, Amengual O, Khamashta MA, Hughes GR: Autoantibodies against malondialdehydemodified lipoprotein(a) in antiphospholipid syndrome. Arthritis Rheum, 1999; 42: 2606-2611
38. Parthasarathy S, Printz DJ, Boyd D, Joy L, Steinberg D: Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis, 1986; 6: 505-510
39. Lamb DJ, Wilkins GM, Leake DS: The oxidative modification of low density lipoprotein by human lymphocytes. Atherosclerosis, 1992; 92: 187-192
40. van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation, 1994; 89: 36-44
41. Wang JJ, Zhang CN, Han AZ, Gong JB, Li K: Percutaneous coronary intervention results in acute increases lipoprotein(a) in patients with acute coronary syndrome and artery disease. Clin Biochem, 2010; 43: 1107-1111